MK3475-522: A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as neoadjuvant therapy and Pembrolizumab vs Placebo as adjuvant therapy for Triple Negative Breast Cancer
CBYL719X2402: A Phase II, Multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of Alpelisib plus Fulvestrant or Letrozole based on prior endocrine therapy, in patients with PIK3CA mutant hormone receptor (HR) positive, Her2-negative advanced breast cancer (aBC), who progressed on or after CDK 4/6 inhibitor treatment.
Last updated on Jan 2018.
Copyright © 2015 National Cancer Centre of Singapore Pte Ltd. All Rights Reserved.
Want to live happier and healthier?
Sign up for our newsletter for practical health tips.
Thanks for subscribing!
You're almost done. Check your email and click the link to confirm your subscription.